

May 1, 2026

Company	Tsubota Laboratory, Inc.	
Representative	President and CEO	Kazuo Tsubota (TSE Growth: 4890)
Contact	Senior Executive Officer, CFO, Head of Corporate Strategy and Operations	Keisuke Mitsuoka (TEL +81-3-6384-2866)

Tsubota Laboratory Announces Violet Light-Enabled Micro-LED Display Technology
Developed in Joint Research with Tohoku University
— Advancing Commercialization of Optical Technologies Beyond Medical Applications —

Tsubota Laboratory, Inc. (Headquarters: Shinjuku-ku, Tokyo, President and CEO: Kazuo Tsubota, hereinafter “the Company”) has developed a display technology incorporating micro-LEDs capable of emitting violet light through joint research with the Graduate School of Engineering at Tohoku University (Professor Takahiro Ishinabe, Professor Yasuyuki Shirai, among others). The Company plans to present this technology in an invited Oral Presentation at Society for Information Display International Symposium (SID Display Week), one of the world’s largest display technology exhibitions, to be held in the United States in May 2026.

Strategic Context:

Grounded in medical insights regarding the potential role of violet light in human health, the Company positions the commercialization of its research outcomes as a core pillar of its management strategy.

Violet light (360–400 nm), a component of outside light, is believed to play important roles in maintaining human health through non-visual photoreceptors (OPN5). Recognizing early on the potential of this light—which is often lacking in modern lifestyles—the Company is advancing the development of medical devices as its primary focus, while also promoting the development of healthcare devices designed to support daily well-being for all.

Presentation Information:

Conference: Society for Information Display International Symposium (SID Display Week)

Presentation format: Invited Oral Presentation

Title: Beyond Image Quality: Violet-Light-Enabled Displays for Visual Health

Date: May 7, 2026 (Local time)

Venue: Los Angeles, U.S.

URL: <https://www.displayweek.org/>

Strategic Significance:


Conventional displays primarily use blue LEDs as their light source and are designed without violet light. In this joint research, we have developed a new technology that enables the emission of violet light while

maintaining conventional display performance by integrating micro-LEDs into the display architecture. This technology enables new value creation through everyday devices by expanding light environment design.

The Company views this initiative as an expansion of its research scope, demonstrating potential applications beyond medical devices into broader consumer and industrial domains.

Key Technology Features:

- By utilizing micro-LEDs at a level that is imperceptible to the human eye, the technology maintains the display quality of conventional screens
- Irradiance control mechanism responsive to user distance
- Compatibility with integration into existing display systems



Display system incorporating proprietary technology

A prototype system incorporates a transparent display module mounted on a tablet device, with violet light being emitted by the built-in micro-LEDs. This demonstrates that violet light can be emitted while maintaining the visibility of the displayed image.

Outlook:

Although this technology is currently in the research and development stage, it is expected to be applicable in the future for displays, educational equipment, wearable devices, and other areas. Going forward, the Company is exploring ways to bring this technology to market through collaboration with display manufacturers and other partners, while also considering business expansion opportunities, including the provision of licenses. This initiative highlights the Company's strategy of leveraging its scientific expertise to create scalable opportunities beyond traditional medical applications.

In addition to research and development in the pharmaceutical and medical device sectors, the Company will create new business opportunities and enhance its long-term corporate value by expanding its optical device business, including into non-medical fields.

Please note that this technology is not a medical device and is not intended for the diagnosis, treatment, or prevention of any disease.

This matter is currently in the research and development stage, and we will continue to consider its future commercialization. At this stage, we do not anticipate any specific revenue, nor have we factored this into our financial forecasts; therefore, the impact on our results is limited. We will promptly announce any matters that need to be disclosed in the future.